Abstract:Introduction Increased expression of αv integrins is frequently associated with tumor cell adhesion, migration, invasion and metastasis, and correlates with poor prognosis in breast cancer. However, the mechanism by which αv integrins can enhance breast cancer progression is still largely unclear. The effects of therapeutic targeting of αv integrins in breast cancer also have yet to be investigated. Methods We knocked down αv integrin in MDA-MB-231 and MCF10A-M4 breast cancer cells, or treated these cells with the αv antagonist GLPG0187. The effects of αv integrin depletion on mesenchymal markers, transforming growth factor-β (TGF-β)/Smad signaling and TGF-β-induced target gene expression were analyzed in MDA-MB-231 cells by RNA analysis or Western blotting. The function of αv integrin on breast cancer cell migration was investigated by transwell assay in vitro , and its effect on breast cancer progression was assessed by both zebrafish and mouse xenografts in vivo . In the mouse model, GLPG0187 was administered separately, or in combination with the standard-of-care anti-resorptive agent zoledronate and the chemotherapeutic drug paclitaxel, to study the effects of combinational treatments on breast cancer metastasis. Results Genetic interference and pharmacological targeting of αv integrin with GLPG0187 in different breast cancer cell lines inhibited invasion and metastasis in the zebrafish or mouse xenograft model. Depletion of αv integrin in MDA-MB-231 cells inhibited the expression of mesenchymal markers and the TGF-β/Smad response. TGF-β induced αv integrin mRNA expression and αv integrin was required for TGF-β-induced breast cancer cell migration. Moreover, treatment of MDA-MB-231 cells with non-peptide RGD antagonist GLPG0187 decreased TGF-β signaling. In the mouse xenografts GLPG0187 inhibited the progression of bone metastasis. Maximum efficacy of inhibition of bone metastasis was achieved when GLPG0187 was combined with the standard-of-care metastatic breast cancer treatments. Conclusion These findings show that αv integrin is required for efficient TGF-β/Smad signaling and TGF-β-induced breast cancer cell migration, and for maintaining a mesenchymal phenotype of the breast cancer cells. Our results also provide evidence that targeting αv integrin could be an effective therapeutic approach for treatment of breast cancer tumors and/or metastases that overexpress αv integrin.

Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Synergism of Rmv-Hu191 with Cisplatin to Treat Gastric Cancer by Acid Sphingomyelinase-Mediated Apoptosis Requiring Integrity of Lipid Raft Microdomains

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Inhibition of Expression of Vascular Endothelial Growth Factor and Its Receptors in Pulmonary Adenocarcinoma Cell by TNP-470 in Combination with Gemcitabine

Molecular Mechanism of Pancreatic Tumor Metastasis Inhibition by Gd@C82(OH)22 and Its Implication for De Novo Design of Nanomedicine.

The Cytoprotective Role Of Gemcitabine-Induced Autophagy Associated With Apoptosis Inhibition In Triple-Negative Mda-Mb-231 Breast Cancer Cells

Mechanistic Study of the Effects of Different Dosages of Gemcitabine on the Migratory and Invasive Abilities of Lung Adenocarcinoma A549 Cells

Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer

Enhanced Antitumor Effect of the Combination of Tumstatin Gene Therapy and Gemcitabine in Murine Models.

Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches

Gemcitabine Inhibits the Micrometastasis of Non-Small Cell Lung Cancer by Targeting the EpCAM-positive Circulating Tumor Cells Via the HGF/cMET Pathway.

Bifidobacterium infantis-Mediated Herpes Simplex Virus-TK/Ganciclovir Treatment Inhibits Cancer Metastasis in Mouse Model

In vitro and in vivo anti-tumor effects of gemcitabine loaded with a new drug delivery system

Combination of Low-Dose Gemcitabine and Recombinant Quail Vascular Endothelial Growth Factor Receptor-2 As a Vaccine Induces Synergistic Antitumor Activities

Antitumor Efficacy of Combination of Interferon-Gamma-inducible Protein 10 Gene with Gemcitabine, a Study in Murine Model

NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells.

MiR-17- 5p/RRM2 regulated gemcitabine resistance in lung cancer A549 cells

Enhanced Anti-Tumor Efficiency of Gemcitabine Prodrug by FAPα-mediated Activation.

Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models

The killing effect of rmhTNF-α combined with gemcitabine on human lune adenocarcinoma cells A549